Skip to main content

The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis

Virologica Sinica volume 30, pages 371–378 (2015)Cite this article

Abstract

Respiratory syncytial virus (RSV) is the key underlying cause of acute lower respiratory tract infection in infants; however, no licensed vaccine against RSV infection is currently available. This study was undertaken to assess the preventive effect of vaccine on RSV infection. In this metaanalysis, 1,792 published randomized clinical trials of RSV vaccines from Jan 1973 to Sep 2015 were examined. Among thirteen studies that met the inclusion criteria, eleven studies estimated the impact of RSV vaccines and four studies estimated the effect of adjuvants. The odds ratios (ORs) were 0.31 (95% CI, 0.15–0.67) and 0.62 (95% CI, 0.29–1.34), respectively. We found that RSV subunit vaccines can significantly reduce the incidence of RSV infection and that whether vaccination with adjuvant therapy was an effective strategy still remained to be studied. This analysis of the preventive effect of vaccines on RSV infection has direct applications for the prevention of RSV infections.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  • Belshe RB, Anderson EL, Walsh EE. 1993. Immunogenicity of purified F glycoprotein of Respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis, 168: 1024–1029.

    Article  CAS  PubMed  Google Scholar 

  • Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F. 2012. Phase 1 study of the safety and immunogenicit of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J, 31: 109–114.

    Article  PubMed  Google Scholar 

  • Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. 2010. New insights for development of a safe and protective RSV vaccine. Hum Vaccin, 6: 482–492.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Bradley JS, Connor JD, Compogiannis LS, Eiger LL. 1990. Exposure of health care workers to ribavirin during therapy for respiratory syncytial virus infections. Antimicrob Agents Chemother, 34: 668–670.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Collins PL, Crowe JE. 2007. Respiratory Syncytial Virus and Metapneumo virus. 5th Edition edn Lippincott Williams&Wilkins, Philadelphia, PA, USA.

    Google Scholar 

  • Collins PL, Graham BS. 2008. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol, 82: 2040–2055.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res, 162: 80–99.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Connors M, Collins PL, Firestone CY, Sotnikov AV, Waitze A, Davis AR, Hung PP, Chanock RM, Murphy BR. 1992. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia—RSV recombinants or RSV. Vaccine, 10: 475–484.

    Article  CAS  PubMed  Google Scholar 

  • Empey KM, Peebles RS, Kolls JK. 2010. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis, 50: 1258–1267.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Falsey AR, Walsh EE. 1996. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine, 14: 1214–1218.

    Article  CAS  PubMed  Google Scholar 

  • Falsey AR, Walsh EE. 1997. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine, 15: 1130–1132.

    Article  CAS  PubMed  Google Scholar 

  • Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, Gorse GJ, Edelman R, Hayden FG, McElhaney JE, Neuzil KM, Nichol KL, Simões EA, Wright PF, Sales VM. 2008. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines—nonadjuvanted vaccine or vaccine adjuvanted with alum—given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis, 198: 1317–1326.

    Article  PubMed  Google Scholar 

  • Falsey AR. 2010. RSV in adults: What do we know? What do we need to know? Where are we going? Paper presented at Proceedings of the 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 2 December.

    Google Scholar 

  • Glezen WP, Taber LH, Frank AL, Kasel JA. 1986. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child, 140: 543–546.

    CAS  PubMed  Google Scholar 

  • Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, Thomas DN, Hickman SP, Kpamegan E, Boddapati S, Piedra PA. 2013. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion proteinnanoparticle vaccine. Vaccine, 7: 524–532.

    Article  Google Scholar 

  • Glenn GM, Fries LF, Thomas DN, Smith G, Kpamegan E, Lu H, Flyer D, Jani D, Hickman SP, Piedra PA. 2015. A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus RecombinantFusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. J Infect Dis, pii: jiv406.

    Google Scholar 

  • Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. 1998. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis, 177: 467–469.

    Article  CAS  PubMed  Google Scholar 

  • Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA. 2009. The burden of respiratory syncytial virus infection in young children. N Engl J Med, 360: 588–598.

    Article  CAS  PubMed  Google Scholar 

  • Harcourt JL, Karron RA, Tripp RA. 2004. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J Infect Dis, 190: 1936–1940.

    Article  CAS  PubMed  Google Scholar 

  • Julian PT, Sally Green. 2000. Cochrane Reviewers Handbook 4.1.1 [updated December 2000]. Oxford.

    Google Scholar 

  • Kaaijk P, Luytjes W, Rots NY. 2013. Vaccination against RSV: Is maternal vaccination a good alternative to other approaches? Human vaccines & immunotherapeutics 9.

    Google Scholar 

  • Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, Li M, Capellan J, Wang E. 2009. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults ≥ 65 years of age. Vaccine, 25: 5913–5919.

    Article  Google Scholar 

  • Mandell GL, Bennett JE, Kelvin GV. 2005. Principles and Practice of Infection Disease.sixth ed edn. Elsevier/Churchill Livingstone, Philadelphia, Pa.

    Google Scholar 

  • Munoz FM, Piedra PA, Glezen WP. 2003. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine, 21: 3465–3467.

    Article  CAS  PubMed  Google Scholar 

  • Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA. 2011. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet, 378: 1917–1930.

    Article  PubMed  Google Scholar 

  • Paradiso PR, Hildreth SW, Hogerman DA, Speelman DJ, Lewin EB, Oren J, Smith DH. 1994. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J, 13: 792–798.

    Article  CAS  PubMed  Google Scholar 

  • Paramore LC, Ciuryla V, Ciesla G, Liu L. 2004. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmaco Economics, 22: 275–284.

    Article  Google Scholar 

  • Piedra PA, Glezen WP, Kasel JA, Welliver RC, Jewel AM, Rayford Y, Hogerman DA, Hildreth SW, Paradiso PR. 1995. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine, 13: 1095–1101.

    Article  CAS  PubMed  Google Scholar 

  • Piedra PA, Grace S, Jewell A, Spinelli S, Bunting D, Hogerman DA, Malinoski F, Hiatt PW. 1996. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J, 15: 23–31.

    Article  CAS  PubMed  Google Scholar 

  • Piedra PA, Grace S, Jewell A, Spinelli S, Hogerman DA, Malinoski F, Hiatt PW. 1998. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis, 17: 217–224.

    Article  CAS  Google Scholar 

  • Piedra PA, Cron SG, Jewell A, Hamblett N, McBride R, Palacio MA, Ginsberg R, Oermann CM, Hiatt PW. 2003. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine, 21: 2448–2460.

    Article  CAS  PubMed  Google Scholar 

  • Rudraraju R, Surman SL, Jones BG, Sealy R, Woodland DL, Hurwitz JL. 2012. Reduced frequencies and heightened CD103 expression among virus-induced CD8(+) T cells in the respiratory tract airways of vitamin A-deficient mice. Clin Vaccine Immunol, 19: 757–765.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Rudraraju R, Jones BG, Sealy R, Surman SL, Hurwitz JL. 2013. Respiratory syncytial virus: current progress in vaccine development. Viruses, 5: 577–594.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. 2011. Viral pneumonia. Lancet, 377: 1264–1275.

    Article  PubMed  Google Scholar 

  • Schepens B, De Baets S, Sedyen K. 2012. He's a novel target for RSV vaccination. Paper presented at Presented at the 8th Respiratory Syncytial Virus Symposium. Santa Fe, NM, USA.

    Google Scholar 

  • Smith G, Raghunandan R, Wu Y, Liu Y, Massare M, Nathan M, Zhou B, Lu H, Boddapati S, Li J, Flyer D, Glenn G. 2012. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One, 7: e50852.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Surman SL, Rudraraju R, Sealy R, Jones B, Hurwitz JL. 2012. Vitamin A deficiency disrupts vaccine-induced antibody-forming cells and the balance of IgA/IgG isotypes in the upper and lower respiratory tract. Viral Immunol, 25: 341–345.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Tayyari F, Marchant D, Moraes TJ Duan W, Mastrangelo P, Hegele RG. 2011. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med, 17: 1132–1135.

    Article  CAS  PubMed  Google Scholar 

  • Techaarpornkul S, Collins PL, Peeples ME. 2002. Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology, 294: 296–304.

    Article  CAS  PubMed  Google Scholar 

  • Thompson WW, Shay DK, Weintraub En, Brammer L, Cox N, Anderson LJ, Fukuda K. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA, 289: 179–186.

    Article  PubMed  Google Scholar 

  • Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P. 1993. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis, 167: 191–195.

    Article  CAS  PubMed  Google Scholar 

  • Weinberg GA, Hall CB, Iwane MK. Poehling KA, Edwards KM, Griffin MR, Staat MA, Curns AT, Erdman DD, Szilagyi PG, New Vaccine Surveillance Network. 2009. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr, 154: 694–699.

    Article  PubMed  Google Scholar 

  • Welliver RC, Tristram DA, Batt K, Sun M, Hogerman D, Hildreth S. 1994. Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine. J Infect Dis, 170: 425–428.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology, School of Basic Medicine, Anhui Medical University, Hefei, 230032, China

    Tongna Zhu, Li Yu, Jingxian Chen, Huan Qiu, Weiwei Lyu & Shenghai Huang

  2. School of Life Science, Anhui Medical University, Hefei, 230032, China

    Shenghai Huang

  3. Department of Pediatrics, the People’s Hospital of Lu’an City, Lu’an, 237005, China

    Chuanlong Zhang

  4. Department of Pathology and Cell Biology, Columbia University, New York, 10032, USA

    Jingxian Chen

Authors
  1. Tongna Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chuanlong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jingxian Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Huan Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weiwei Lyu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shenghai Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shenghai Huang.

Additional information

ORCID: 0000-0003-4072-812X

These authors contributed equally to this work.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhu, T., Zhang, C., Yu, L. et al. The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis. Virol. Sin. 30, 371–378 (2015). https://doi.org/10.1007/s12250-015-3630-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12250-015-3630-3

Keywords

  • respiratory syncytial virus (RSV)
  • vaccine prophylaxis
  • meta-analysis